

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong under the Companies Ordinance)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

“PACLITAXEL CATIONIC LIPOSOME FOR INJECTION” FOR THE TREATMENT OF BREAST CANCER WAS GRANTED CLINICAL TRIAL APPROVAL

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that “paclitaxel cationic liposome for injection” developed by the Group (the “**Product**”) was granted approval by the National Medical Products Administration to conduct clinical trials in China.

The Product is a class 2 chemical drug and the approved clinical indication is breast cancer. The pre-clinical studies indicated that the Product achieved anti-cancer effect through dual mechanism of inhibiting the mitosis of tumor cells and inhibiting the replication of angiogenic endothelial in tumor, and has outstanding in vivo efficacy with characteristics of good safety and pharmacokinetics, providing a promising prospect of demonstrating good efficacy for the treatment of breast cancer in the clinical studies.

Given the favorable results in the non-clinical studies, the Group will endeavor to push forward with the clinical trials of the Product and strive to launch the Product as soon as possible for the sake of the patients in the world.

By Order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 25 April 2019

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LU Hua, Dr. LI Chunlei, Mr. ZHANG Cuilong, Dr. WANG Qingxi and Mr. CHAK Kin Man as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Prof. LO Yuk Lam, Dr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors.